Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

Tak, P.P.; Rigby, W.F.; Rubbert-Roth, A.; Peterfy, C.G.; van Vollenhoven, R.F.; Stohl, W.; Hessey, E.; Chen, A.; Tyrrell, H.; Shaw, T.M.

Published in:
Annals of the Rheumatic Diseases

DOI:
10.1136/ard.2010.137703

Citation for published version (APA):
Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

P P Tak,1 W F Rigby,2 A Rubbert-Roth,3 C G Peterfy,4 R F van Vollenhoven,5 W Stohl,6 E Hessey,7 A Chen,8 H Tyrrell,7 T M Shaw,7 for the IMAGE Investigators

Abstract

Objectives Rituximab is an effective treatment in patients with established rheumatoid arthritis (RA). The objective of the IMAGE study was to determine the efficacy of rituximab in the prevention of joint damage and its safety in combination with methotrexate (MTX) in patients initiating treatment with MTX.

Methods In this double-blind randomised controlled phase III study, 755 MTX-naive patients with active RA were randomly assigned to MTX alone, rituximab 2×500 mg + MTX or rituximab 2×1000 mg + MTX. The primary end point at week 52 was the change in joint damage measured using a Genant-modified Sharp score.

Results 249, 249 and 250 patients were randomly assigned to MTX alone, rituximab 2×500 mg + MTX or rituximab 2×1000 mg + MTX compared with MTX alone was associated with a reduction in progression of joint damage (mean change in total modified Sharp score 0.359 vs 1.079; p=0.0004) and an improvement in clinical outcomes (ACR50 65% vs 42%; p<0.0001); rituximab 2×500 mg + MTX improved clinical outcomes (ACR50 59% vs 42%; p<0.0001) compared with MTX alone but did not significantly reduce the progression of joint damage. Safety outcomes were similar between treatment groups.

Conclusions Treatment with rituximab 2×1000 mg in combination with MTX is an effective therapy for the treatment of patients with MTX-naive RA. ClinicalTrials.gov identifier NCT00299104.

Introduction

Rheumatoid arthritis (RA) is a chronic inflammatory disease in which early aggressive treatment with disease-modifying antirheumatic drugs (DMARDs) can improve outcomes and prevent joint damage. Treatment recommendations for the management of early arthritis concluded that the main goal of treatment is clinical remission, in order to prevent structural joint damage and long-term disability.1 2 These recommendations acknowledge that patients with disease features of poor prognosis—for example, high disease activity and the presence of autoantibodies (rheumatoid factor (RF) and/or anticitrullinated peptide antibodies (ACPA))—should be considered as candidates for the early introduction of biological therapies.

Incorporating biological therapies into early treatment regimens has shown that remission of disease with inhibition of progressive joint destruction is an achievable treatment goal, although this has primarily been limited to biological agents that share a common mechanism of action—namely, inhibition of tumour necrosis factor (TNF).3-6

Rituximab is a therapeutic monoclonal antibody that selectively depletes CD20+B cells. The combination of rituximab with methotrexate (MTX) significantly improves disease symptoms in patients with RA who have an inadequate response to conventional DMARD therapy, and ameliorates disease symptoms and protects against joint damage in patients who have had an inadequate response to TNF inhibitors.7-9 The aim of this study was to investigate the early therapeutic introduction of rituximab in patients with active RA not previously treated with MTX.

Methods

Patients Patients were recruited between January 2006 and September 2007 from 169 centres in Europe, the USA, Latin America, Asia and Australia. Eligible patients were aged 18–80 years with RA diagnosed according to the revised 1987 American College of Rheumatology (ACR) criteria.10 Disease duration was ≥8 weeks but ≤4 years. Patients were not to have received previous treatment with MTX and were to have active disease defined as a swollen joint count (66 joints) and tender joint count (68 joints) both ≥3 at screening and baseline, and C-reactive protein (CRP) ≥1.0 mg/dl. Patients seronegative for RF required radiographic evidence of erosive damage attributable to RA.

This study was conducted in accordance with the ethical principles of the Declaration of Helsinki and adhered to the principles outlined in the Guideline for Good Clinical Practice ICH Tripartite Guideline (January 1997).

Procedures Patients were randomised to receive rituximab (2×500 mg or 2×1000 mg) or placebo in addition to initiating MTX. The randomisation schedule, stratified by region (USA or rest of world) and RF status (positive or negative), was generated by the sponsor and supplied to an Interactive Voice Response System (IVRS). At randomisation, patients were assigned unique medication and randomisation numbers via the IVRS. The sponsor, investigators and patients were blinded to treatment allocation until week 52, at which time the sponsor was unblinded for the purposes of data analysis. Rituximab/placebo was administered by intravenous infusion on days 1 and 15, with all
Disease Activity Score in 28 joints (DAS28-ESR) ≥2.6. Patients eligible for re-treatment were those with DAS28-ESR <2.6 who were re-treated if and when this increased to ≥2.6. Further courses were permitted 24 weeks following each course based on the same criteria.

Concomitant glucocorticoids (≤10 mg/day prednisolone or equivalent) and non-steroidal anti-inflammatory drugs were permitted with doses kept stable. Intravenous or intramuscular glucocorticoids and additional DMARDs (non-biological or biological) were prohibited.

Radiographs of the hands, wrists and feet were performed at screening (considered baseline), week 24 and week 52, and read at a central reading facility (Synarc Inc, San Francisco, California, USA) by two independent expert radiologists, blinded to treatment and sequence, using the Genant-modified Sharp scoring system (range 0–290). The primary end point of the study was the change in total Genant-modified Sharp score (mTSS) from baseline to week 52. Clinical outcomes at week 52 included the proportion of patients achieving ACR responses relating to 20%, 50%, 70% and 90% improvement from baseline, responses defined according to the criteria of the European League Against Rheumatism (EULAR) and change in DAS28-ESR. Durability of response was determined by the proportion of patients achieving a major clinical response (MCR; defined as maintenance of ACR70 response ≥6 months). Physical function was determined using the Health Assessment Questionnaire-Disability Index (HAQ-DI), including the proportion of patients achieving minimum clinically important differences (MCID; an improvement of ≥0.22).

Adverse events were recorded throughout the study and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.

Statistical analysis
Based on simulations using distributions that match the data published from the ASPIRE study, with data analysed using non-parametric tests and the closure principle for multiplicity adjustment, a planned sample size of 250 patients per group was expected to give >90% power to detect differences between each rituximab group and MTX alone.

Radiographic analyses were performed on a modified intent-to-treat (mITT) population, defined as randomised patients who received study medication and for whom a baseline and at least one post-baseline x-ray were available. Missing values at week 52 were imputed by linear extrapolation. For changes in radiographic scores, a global test was performed using the Kruskal–Wallis test to control for multiplicity; with primary comparisons made using a non-parametric test (Van Elteren) for the individual rituximab dose groups versus MTX alone, adjusting for baseline stratification factors (region and RF status). The difference in the proportions of patients without radiographic progression was tested using the Cochran–Mantel–Haenszel (CMH) test, also adjusting for baseline stratification factors; if progression status could not be determined, the patient was classed as ‘progressed’. Radiographic non-progression was defined as a change in total modified Sharp score ≤0.

Clinical efficacy of rituximab versus placebo was analysed using the CMH test for categorical end points and analysis of variance (ANOVA) for continuous end points, adjusting for baseline stratification factors. ANOVA models also included the end point baseline value if applicable (eg, for analysis of change in DAS28-ESR and HAQ-DI). Missing data were imputed using the non-responder method for ACR, EULAR and MCR (all patients who withdrew or received a non-permitted DMARD were classed as non-responders) and the last observation carried forward for all other end points.

RESULTS
Overall, 755 patients were randomised with 748 included in the ITT and safety analyses and 715 in the mITT analysis for radiographic outcomes. Baseline demographic and disease characteristics were balanced across treatment groups and indicated that this was an early MTX-naive RA population with highly active disease (mean DAS28-ESR 7.0–7.1, mean tender joint count 32.7–34.0, mean swollen joint count 20.0–22.4) and a high degree of functional impairment (table 1). Approximately

| Table 1 Baseline demographic and disease characteristics (intent-to-treat population) |
|---------------------------------------------|----------------|----------------|----------------|
| Placebo + MTX (n=249) | Rituximab (2×500 mg) + MTX (n=249) | Rituximab (2×1000 mg) + MTX (n=250) |
| Female | 192 (77%) | 203 (82%) | 212 (85%) |
| Age (years) | 48.1 (12.7) | 47.9 (13.4) | 47.9 (13.3) |
| Disease duration (years) | Mean (SD) | 0.91 (1.1) | 0.99 (1.1) | 0.92 (1.3) |
| Median (range) | 0.4 (0.01–3.37) | 0.5 (0.00–3.95) | 0.4 (0.01–11.88) |
| Percentage with disease duration <2 years | 86 | 80 | 83 |
| No previous DMARD therapy | 174 (70%) | 178 (72%) | 172 (69%) |
| Receiving concomitant corticosteroids | 119 (48%) | 117 (47%) | 111 (44%) |
| Receiving concomitant NSAIDs and/or COX-2 inhibitors | 173 (69%) | 179 (72%) | 191 (78%) |
| Swollen joint count 0–66 possible joints | 20.0 (12.9) | 22.4 (12.8) | 21.6 (11.0) |
| Tender joint count 0–66 possible joints | 32.7 (16.6) | 34.0 (15.7) | 33.2 (15.9) |
| C-reactive protein (mg/dl) | 3.2 (2.8) | 3.4 (3.1) | 3.0 (2.7) |
| Health Assessment Questionnaire (0–3 range) | 1.8 (0.6) | 1.8 (0.7) | 1.7 (0.7) |
| DAS28-ESR | 7.1 (1.0) | 7.1 (1.0) | 7.0 (1.0) |
| Rheumatoid factor positive | 217 (87%) | 216 (87%) | 213 (85%) |
| Baseline mean mTSS | 7.4 (10.9) | 7.7 (11.7) | 6.9 (10.6) |

Data are mean (SD) or number (%) unless otherwise stated.

COX-2, cyclo-oxygenase-2; DAS28, Disease Activity Score in 28 joints; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; mTSS, Genant-modified total Sharp score; MTX, methotrexate; NSAID, non-steroidal anti-inflammatory drug.
A cumulative probability plot showing the change from baseline to week 52 in mTSS for the ITT population (figure S1). Sensitivity analyses, including the per-protocol analysis, supported robustness of the primary outcome. The difference was >18 mg/week in all groups by week 8 (median dose of MTX 19–20 mg/week).

At the week 52 primary endpoint, rituximab 2×1000 mg + MTX was associated with a significant reduction in the progression of joint damage compared with MTX alone (mean change in mTSS 0.359 vs 1.079; p=0.0004; table 2). The mean dose of MTX was >18 mg/week in all groups by week 8 (median dose 19–20 mg/week).

Although slower progression of joint damage was also observed with rituximab 2×500 mg + MTX, the difference did not achieve statistical significance compared with MTX alone. An exploratory analysis indicated that rituximab 2×1000 mg + MTX resulted in slower progression of joint damage versus rituximab at the lower dose (p=0.0369). This apparent difference between the rituximab doses was extensively explored across most end points including significantly higher proportions of patients achieving ACR20, 50, 70 and 90 responses (table 2). MCRs were achieved in 8%, 18% (p=0.0015) and 21% (p<0.0001) of patients in the MTX alone, rituximab 2×500 mg and rituximab 2×1000 mg groups, respectively.

Greater decreases from baseline in DAS28-ESR were observed in both the rituximab 2×500 mg and 2×1000 mg groups compared with MTX alone from week 0 through to week 52 (figure S2B), with significant differences from baseline observed at week 52 versus MTX alone (adjusted mean −3.05 and −3.21 vs −2.06; p<0.0001 for both). Within both rituximab groups the incidence of remission (defined as DAS28-ESR <2.6) increased throughout the study period and by week 52 was achieved in 13%, 25% and 31% in the MTX alone, rituximab 2×500 mg and rituximab 2×1000 mg groups, respectively (p<0.001 for both rituximab groups; see table S2 and figure S2 in online supplement). EULAR good responses were achieved in significantly higher proportions of patients in both rituximab groups versus MTX (table 2).

Improvement in function as determined by mean changes in the HAQ-DI from baseline to week 52 was significantly greater in the rituximab 2×500 mg and 2×1000 mg groups compared with MTX alone (−0.905 and −0.916 vs −0.628, respectively; p<0.0001 for both), with higher proportions of patients achieving an MCID than in the MTX alone group (table 2).

### Efficacy in subgroups

Subgroup analysis indicated that treatment effects were observed across multiple end points in the majority of subgroups based on baseline characteristics (change in mTSS across subgroups is shown in table S1 in the online supplement). This included patients with high disease activity, elevated inflammatory markers, and RF- and/or ACPA-seropositive disease. Responses in patients seropositive for RF and/or ACPA were enhanced compared with patients seronegative for both autoantibodies across most end points (table 2). As with all subgroups with relatively small sample sizes, the data in the seronegative subgroup should be interpreted with caution.

### Safety outcomes

Adverse events were reported in 81%, 76% and 79% of patients treated with MTX alone, rituximab 2×500 mg or rituximab 2×1000 mg, respectively, with serious adverse events in 10%, 9% and 10%, respectively (table 3). Adverse events leading to withdrawal included exacerbation of RA (five patients in the MTX alone group) and infusion-related reactions (one patient in the rituximab 2×500 mg group and three patients in the rituximab 2×1000 mg group). There were three deaths (two cases of pneumonia, including a case of Pneumocystis jiroveci pneumonia (PJP) and one cerebral infarct), all of which occurred in the MTX alone group.
Table 2  Summary of efficacy outcomes

<table>
<thead>
<tr>
<th></th>
<th>Total population</th>
<th>Seropositive (RF + ve and/or ACPA +ve) subgroup</th>
<th>Seronegative (RF -ve and ACPA -ve) subgroup</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo + MTX</td>
<td>Rituximab (2×500 mg) + MTX</td>
<td>Placebo + MTX</td>
</tr>
<tr>
<td>Week 52</td>
<td>n=232</td>
<td>n=239</td>
<td>n=244†</td>
</tr>
<tr>
<td>Change in mTSS (mean)</td>
<td>1.079</td>
<td>0.646</td>
<td>0.359**</td>
</tr>
<tr>
<td>% patients with no progression OR (unadjusted)</td>
<td>53</td>
<td>58</td>
<td>64*</td>
</tr>
<tr>
<td>95% CI</td>
<td>0.827 to 1.712</td>
<td>1.051 to 2.189</td>
<td>1.438</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.979 to 2.114</td>
<td>0.936 to 12.743</td>
</tr>
<tr>
<td>Week 24</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in mTSS (mean)</td>
<td>0.701</td>
<td>0.580</td>
<td>0.328**</td>
</tr>
<tr>
<td>% patients with no progression OR (unadjusted)</td>
<td>59</td>
<td>63</td>
<td>70*</td>
</tr>
<tr>
<td>ITT</td>
<td>n=249</td>
<td>n=249</td>
<td>n=250</td>
</tr>
<tr>
<td></td>
<td></td>
<td>n=227</td>
<td>n=224</td>
</tr>
<tr>
<td>Disease activity outcomes (ITT population) week 52</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACR20</td>
<td>64%</td>
<td>77%*</td>
<td>80%***</td>
</tr>
<tr>
<td>ACR50</td>
<td>42%</td>
<td>59%***</td>
<td>65%***</td>
</tr>
<tr>
<td>OR (unadjusted)</td>
<td>2.043</td>
<td>2.567</td>
<td>2.915</td>
</tr>
<tr>
<td>95% CI</td>
<td>1.430 to 2.919</td>
<td>1.788 to 3.685</td>
<td>1.986 to 4.278</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1.308 to 3.146</td>
<td></td>
</tr>
<tr>
<td>ACR70</td>
<td>25%</td>
<td>42%***</td>
<td>47%***</td>
</tr>
<tr>
<td>ACR90</td>
<td>9%</td>
<td>17%*</td>
<td>16%*</td>
</tr>
<tr>
<td>Major clinical response</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ACRfn</td>
<td>19.5</td>
<td>42.9***</td>
<td>46.0***</td>
</tr>
<tr>
<td>EULAR good response</td>
<td>18%</td>
<td>39%***</td>
<td>42%***</td>
</tr>
<tr>
<td>DAS28-ESR LDA</td>
<td>20%</td>
<td>40%***</td>
<td>43%***</td>
</tr>
<tr>
<td>DAS28-ESR remission</td>
<td>13%</td>
<td>25%**</td>
<td>31%***</td>
</tr>
<tr>
<td>Physical function outcomes week 52</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Change in HAQ-DI (mean)†</td>
<td>−0.628</td>
<td>−0.905***</td>
<td>−0.916***</td>
</tr>
<tr>
<td>% With HAQ-DI decrease ≥0.22</td>
<td>77</td>
<td>87*</td>
<td>88*</td>
</tr>
</tbody>
</table>

*p<0.05, **p<0.001, ***p<0.0001 for differences vs placebo + MTX.
†Total number of patients included in rituximab 2×1000 mg autoantibody subgroups differed by two versus total number of patients included in rituximab 2×1000 mg group throughout because two patients could not be classified (RF-negative but no ACPA data, so unable to be assigned to either group).
‡Adjusted mean presented for total population; standard mean presented for subgroups (where available). Analyses included baseline scores as additional covariates.
§No statistical analysis was performed on the subgroup data.
Van Etern test for difference in distribution of changes in radiographic variables; ANOVA model adjusted for stratification factors (RF, region) (adjusted mean changes shown in table) for all other continuous variables; Cochran–Mantel–Haenszel test for categorical variables; non-responder imputation used for ACR major clinical response and EULAR response variables; last observation carried forward.
ACP, anti-citrullinated peptide antibodies; ACR, American College of Rheumatology; ACRfn, American College of Rheumatology Index of Improvement in Rheumatoid Arthritis; ANOVA, analysis of variance; DAS28, Disease Activity Score in 28 joints; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; HAQ-DI, Health Assessment Questionnaire-Disability Index; ITT, intent-to-treat; LDA, low disease activity; mITT, modified intent-to-treat; mTSS, Genant-modified total Sharp score; MTX, methotrexate; nc, not calculated; RF, rheumatoid factor.
DISCUSSION

This is the first study of initiating a targeted B cell therapy in MTX-naïve patients with active RA. Over 52 weeks the study showed that, compared with MTX alone, rituximab 2×1000 mg + MTX was significantly more effective in inhibiting the progression of joint damage and in improving clinical outcomes in a population of patients with RA, of whom approximately 90% were seropositive for RF and/or ACPA autoantibodies. Although the lower dose of rituximab (2×500 mg) was associated with improved symptoms, this dose did not meet the primary end point of reducing joint damage.

Both doses of rituximab were highly effective in relieving the signs and symptoms of RA. Importantly, the proportions of patients achieving high-hurdle end points, including those with 90% improvement in their disease symptoms (ACR90)
Table 3  Summary of safety profile over 52 weeks (safety population)

<table>
<thead>
<tr>
<th></th>
<th>Placebo + MTX (n=250)</th>
<th>Rituximab (2×500 mg) + MTX (n=249)</th>
<th>Rituximab (2×1000 mg) + MTX (n=249)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treated first course</td>
<td>250</td>
<td>249</td>
<td>249</td>
</tr>
<tr>
<td>Patient-years of observation</td>
<td>229.75</td>
<td>238.77</td>
<td>241.06</td>
</tr>
<tr>
<td>AE incidence: no. of patients (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any AE</td>
<td>203 (81%)</td>
<td>189 (76%)</td>
<td>197 (78%)</td>
</tr>
<tr>
<td>Any serious AE</td>
<td>26 (10%)</td>
<td>23 (9%)</td>
<td>24 (10%)</td>
</tr>
<tr>
<td>Serious AE in &gt;1 patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumonia</td>
<td>3 (1%)</td>
<td>1 (&lt;1%)</td>
<td>2 (&lt;1%)</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>2 (&lt;1%)</td>
<td>1 (&lt;1%)</td>
<td>–</td>
</tr>
<tr>
<td>Appendicitis</td>
<td>–</td>
<td>2 (&lt;1%)</td>
<td>–</td>
</tr>
<tr>
<td>RA flare</td>
<td>1 (&lt;1%)</td>
<td>–</td>
<td>2 (&lt;1%)</td>
</tr>
<tr>
<td>AE leading to withdrawal</td>
<td>12 (5%)</td>
<td>4 (2%)</td>
<td>5 (2%)</td>
</tr>
<tr>
<td>Death</td>
<td>3 (1%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Infusion-related reaction</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First course*</td>
<td>31 (12%)</td>
<td>35 (14%)</td>
<td>46 (18%)</td>
</tr>
<tr>
<td>Second course*</td>
<td>20 (10%)</td>
<td>19 (9%)</td>
<td>22† (10%)</td>
</tr>
<tr>
<td>Third course*</td>
<td>7 (6%)</td>
<td>2 (2%)</td>
<td>9 (10%)</td>
</tr>
<tr>
<td>Serious infusion-related reactions</td>
<td>–</td>
<td>–</td>
<td>1 (&lt;1%)†</td>
</tr>
<tr>
<td>Infection</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>124 (50%)</td>
<td>127 (51%)</td>
<td>129 (52%)</td>
</tr>
<tr>
<td>Serious§</td>
<td>13 (5%)</td>
<td>6 (2%)</td>
<td>8 (3%)</td>
</tr>
<tr>
<td>Cardiac event</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>3 (1%)</td>
<td>3 (1%)</td>
<td>8 (3%)</td>
</tr>
<tr>
<td>Serious</td>
<td>–</td>
<td>2 (&lt;1%)</td>
<td>3 (1%)</td>
</tr>
<tr>
<td>Vascular event</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>17 (7%)</td>
<td>19 (8%)</td>
<td>21 (8%)</td>
</tr>
<tr>
<td>Serious</td>
<td>2 (&lt;1%)</td>
<td>2 (&lt;1%)</td>
<td>1 (&lt;1%)</td>
</tr>
<tr>
<td>Malignancy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any</td>
<td>5 (2%)</td>
<td>2 (&lt;1%)</td>
<td>1 (&lt;1%)</td>
</tr>
<tr>
<td>Serious</td>
<td>4 (2%)</td>
<td>2 (&lt;1%)</td>
<td>1 (&lt;1%)</td>
</tr>
<tr>
<td>AE rates per 100 patient-years (95% CI)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Overall infection rate</td>
<td>115 (101.85 to 129.6)</td>
<td>103.87 (91.71 to 117.6)</td>
<td>126.52 (113.09 to 141.5)</td>
</tr>
<tr>
<td>Serious infection rate</td>
<td>6.09 (3.61 to 10.29)</td>
<td>4.61 (2.55 to 8.32)</td>
<td>3.73 (1.94 to 7.18)</td>
</tr>
</tbody>
</table>

*Percentage incidence based on number receiving each treatment course.
†One of these infusion-related reactions was reported as serious.
‡Anaphylactic reaction during the second infusion of the second course.
§Reported as serious and/or treated with intravenous antibiotics.

AE, adverse event; MTX, methotrexate; RA, rheumatoid arthritis.

as well as those achieving DAS28-ESR remission, were significantly greater with rituximab + MTX compared with MTX alone. Responses were sustained over time, as demonstrated by significantly higher proportions of patients achieving an MCR in both rituximab groups. Functional ability was also improved with significantly greater mean changes in the HAQ-DI in both rituximab treatment groups compared with MTX alone, as well as higher proportions of patients achieving clinically meaningful changes. Given that the HAQ-DI is a major predictor of work disability as well as costs of disease treatment, its significant improvement in this young and functionally impaired patient population is of particular clinical relevance.

Rituximab 2×1000 mg significantly reduced the progression of joint damage within 6 months. Importantly, the degree of inhibition was notably greater from weeks 24 to 52, with a 91% reduction in the progression of joint damage compared with MTX alone. Exploratory analysis also showed significant effects on reducing joint damage in the rituximab 2×500 mg group during this second 6-month period. The slower onset of radiographic inhibition with this dose is in contrast to that observed for clinical outcomes, which were comparable over time for both doses of rituximab (figure 2B). Disconnects between clinical responses and radiographic outcomes with rituximab and with TNF inhibitors have been reported, however, the finding that different doses of the same therapeutic agent have similar clinical effects but differential radiographic outcomes is unusual. A definitive explanation is unknown; however, one hypothesis may be related to the ability of the rituximab 2×1000 mg dose to induce more complete B cell depletion in non-peripheral compartments. In this model, more pronounced depletion of synovial B-lineage cells is required for radiographic relative to clinical outcomes. Thus, the influence of B cells may have a different dynamic to the effects that are related to clinical responses. This hypothesis may be supported by studies in monkeys, which have shown greater B cell depletion in lymphoid tissues following repeat treatments. Given that a high proportion of patients in all groups received re-treatment in the current study, more complete depletion in the synovium following re-treatment may provide some explanation as to the enhanced effect on joint damage observed in the second half of the study.

This observation also suggests that the labelled dose of rituximab 2×1000 mg remains appropriate since this was the only dose that both improved clinical symptoms and significantly inhibited progression of joint damage. However, whether continued repeat treatment with this dose or the lower dose of 2×500 mg is optimal has not been addressed in this study and is perhaps an area for further investigation.

Importantly, compared with MTX alone, improved clinical and radiographic outcomes were observed with rituximab + MTX in patients with accepted markers of progressive disease (eg, high disease activity or CRP). Consistent with previous
damage and improved functional ability were all significant critical treatment goals of disease remission, inhibition of joint depletion with rituximab 2×1000 mg + MTX is an effective and well-tolerated therapy for the treatment of MTX-naïve RA. The critical treatment goals of disease remission, inhibition of joint damage and improved functional ability were all significantly improved compared with the standard of care treatment (MTX) in this important patient population.

Acknowledgements
The authors thank Laura Burke, Chris Mela, Lesley Gazely and Gillian Armstrong (Roche Products Ltd) who all contributed to the analysis and interpretation of the data. Support for third-party writing assistance for this manuscript, furnished by Julie Gray, was provided by Adelphi Communications. The authors were responsible for critical revisions of the manuscript and for important intellectual content.

IMAGE Investigators
Aeelon J (Arthritis Clinic, Jackson, TN, USA); Afif N (Centre Hospitalier De Mulhouse-Hôpital, Emile Muller, France); Afshar M (Central Sarasota, Västerås, Sweden); Aires F (Hospital Universitário De Brasília, Brazil); Alanis R (Clinica San Jose, Obregón, Mexico); Alonso C (Centro De Investigacion Del Noroeste, S.C. Tijuana, Mexico); Allen R (E Schlossklinik Klinik, Berlin, Germany); Alvaro-Gracia JM (Hospital De La Princesa, Madrid, Spain); Asratzadeh A (Pacific Arthritis Care Center, Los Angeles, CA, USA); Ballina J (Hospital University Central, De Asturias, Oviedo, Spain); Bambara L-P (Poliklinic G B. Rossi, Verona, Italy); Bao C (Renji Hospital, Shanghai, China); Bell M (Sunnybrook Health Science Centre, Toronto, Canada); Bemsey S (Louisiana State University Medical Center, Shreveport, LA, USA); Bessette L (Groupe De Recherche En Rhumatologie et Maladies Osteoarticulaires, Quebec, Canada); Barbosa C (Clinical Pharmacology Study Group, Worcester, MA, USA); Boling E (Boling Clinical Trials, Upland, CA, USA); Bourgeois P (Hôpital Pitie-Salpêtrière, Paris, France); Braun J (Rheumatozentrum-Ruehrberg, St Josiefs-Krankenhaus, Herne, Germany); Briones H (Private Practice, Guatemala City, Guatemala); Brezicki J (Wojewodzki Spital, Zaspylon, Elblag, Poland); Burgos-Vargas R (Clínica Para E Diagnostico y Tratamiento Reumatologicas Sc, Mexico City, Mexico); Burmester G (Charité–Univers Medizin, Berlin, Germany); Burnett M (Tampa Medical Group, Tampa, FL, USA); Busch H (Family Arthritis Center, Jupiter, FL, USA); Cabello E (Hospital Alberto, Sabogal, Lima, Peru); Cai D (Columbia University, New York, USA); Calvo A (Clinica San Felipe, Lima, Peru); Cantagrel A (Hospital Rangueil, Toulouse, France); Cantini F (Ospedale Miserendino, Dolce, Prato, Italy); Carlos Zea A (Hospital Ramon y Cajal, Madrid, Spain); Carreño Perez L (Hospital Ramon Y Cajal, Madrid, Spain); Carpio R (Hospital Christus Muguerza Del Parque, Chihuahua, Mexico); Cheoi Shim S (Eilji University Hospital, Daejeon, South Korea); Chindalore V (Pinnacle Research Group, Aniston, AL, USA); Chiriac R (Reumacentro Sac, Lima, Peru); Cheo J (Asian Hospital and Medical Center, Manila, Philippines); Jeka S (Spital Wojewodzki Im, Dr Jana Biza, Bydgoszcz, Poland); Jimenez R (Seattle Arthritis Clinic, Seattle, WA, USA); Jones G (Menyes Research Institute, University of Tasmania, Hobart, Tasmania); Jones R (Clinic for Rheumatic Diseases, Tuscaloosa, AL, USA); Karne J (Sanosato Arthritis Center, Sarasota, FL, USA); Kashi G (Arthritis and Osteoporosis Consultants of Charleston, SC, USA); Klauffmann B (Skeiklinikken, Sarpsborg, Norway); Hilliquin P (Hospital Urd Francilien Corbeil-Essonnes, France); Holt D (Hospital Alberto Sabto Spartanburg Medical Research Spartenburg, SC, USA); Huang F (General Hospital of Chinese PLA, Beijing, China); Huff J (Arthritis and Osteoporosis Center of South Texas, San Antonio, TX, USA); Huizinga T (Academisch Ziekenhuis Leiden, Leiden, The Netherlands); Issacs J (Freeman Hospital, Newcastle upon Tyne, UK); Jaffer A (Allergy and Rheumatism Center, La Jolla, CA, USA); Jason Amato E (Saint John’s Hospital and Medical Center, Manila, Philippines);}

For RF or ACPA at baseline compared with patients who were seronegative for both.

The safety profile in this early RA cohort is consistent with that published with rituximab in patients with later stage disease with no new or unexpected safety findings observed. The rate of serious infection was low and consistent with rates previously published for rituximab in RA. Two opportunistic infections were reported, both of which were cases of PJP (including one in a patient receiving MTX alone with a fatal outcome). Although the incidence of PJP in patients with RA is thought to be low, these have been reported with low-dose MTX as well as in patients treated with biological therapies.

With the exception of the frequency of infusion-related reactions to the first infusion of the first treatment course, the safety profiles between the two rituximab dose groups were comparable.

In summary, this is the first evidence that targeted B cell depletion with rituximab 2×1000 mg + MTX is an effective and well-tolerated therapy for the treatment of MTX-naïve RA. The critical treatment goals of disease remission, inhibition of joint damage and improved functional ability were all significantly improved compared with the standard of care treatment (MTX) in this important patient population.
et al. EW, 3 . et al. Saag
Combe
Not commissioned; externally peer reviewed. The study was approved by the institutional review board or the
paid lecture fees and received grant support from Roche. WS has served as a paid
services to pharmaceutical companies. RFvV has served as a paid consultant, been
Roche and Wyeth Pharmaceuticals. WFR has served as a paid consultant for Roche,
MedImmune Limited, Merck Serono SA, Novartis Pharma AG, NovoNordisk A/S,
commercial entity that sponsored the study (Roche), and received grant support
lecture fees by Abbott Laboratories Ltd and Roche and received a payment from a
NovImmune, NovoNordisk, Roche and Wyeth Pharmaceuticals. He has been paid
Therapeutics, GlaxoSmithKline, Johnson and Johnson, Merck Serono, Novartis,
Ltd, Astellas, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Funxional
PPT has served as a paid consultant to Abbott Laboratories
California Keck School of Medicine, Los Angeles, CA, USA.

Competing interests PPT has served as a paid consultant to Abbott Laboratories Ltd, Astellas, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Functional Therapeutics, GlaxoSmithKline, Johnson and Johnson, Merck Serono, Novartis, Novimmune, Novo Nordisk, Roche and Wyeth Pharmaceuticals. He has been paid
lecture fees by Abbott Laboratories Ltd and Roche and received a payment from a
corporate entity that sponsored the study (Roche), and received grant support from
the Netherlands Organization for Health Research and Development (ZonMW) in
assignment of the Netherlands Organization for Scientific Research (NWO), the
Dutch Arthritis Association, the European Community, SmartMix CenterNovem (NWO and the Dutch Ministry of Economic Affairs), Bristol-Myers Squibb Int. Corp, MedImmune Limited, Merck Serono SA, Novartis Pharma AG, Novo Nordisk A/S, Roche and Wyeth Pharmaceuticals. WFR has served as a paid consultant for Roche, Genentech and Biogen Idec, has been paid lecture fees by Genentech and Biogen Idec and has received grant support from Roche. AR-R has served as a paid consultant to Roche, Wyeth, Chugai, Essex and been paid lecture fees by Roche, UCB and Bristol-Myers Squibb. GGP is an employee of Spire Sciences LLC which provides clinical trial services to pharmaceutical companies. RFV has served as a paid consultant, been
paid lecture fees and received grant support from Roche. WS has served as a paid
consultant to Human Genome Sciences and has received grant support from NIAMS, Genentech, Human Genome Sciences, Arthritis Foundation Southern California, Chapter and Xencor. EH holds shares in Roche and is an employee of Roche. AC is an
employee of Genentech, a member of the Roche Group. HT is an employee of Roche
and has received payment from a commercial entity that sponsored the study. TMS holds
shares in Roche and is an employee of Roche.

Ethics approval The study was approved by the institutional review board or the
ethics committee at each study site. All patients gave written informed consent.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES
1. Combe B, Landewe R, Luken C, et al. EULAR recommendations for the manage-
ment of early arthritis: report of a task force of the European Standing Committee for
International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis
College of Rheumatology. 2008 recommendations for the use of nonbiologic and bio-
logic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum
Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset
Study Group. Combination of infliximab and methotrexate therapy for early rheuma-
multicenter, randomized, double-blind clinical trial of combination therapy with
adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in
patients with early, aggressive rheumatoid arthritis who had not had previous
5. Klareskog L, van der Heide D, de Jager JJ, et al. TEMPO (Trial of Etanercept and
Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic
effect of the combination of etanercept and methotrexate compared with each treat-
ment alone in patients with rheumatoid arthritis: double-blind randomised controlled
with a combination of methotrexate and etanercept in active, early, moderate to severe
rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.
rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a
multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating
8. Emery P, Deodhar A, Rigby WE, et al. Efficacy and safety of different doses and
retreatment of rituximab: a randomised, placebo-controlled trial in patients who are
biological naïve with active rheumatoid arthritis and an inadequate response to
methotrexate (Study Evaluating Rituximab’s Efficacy in MTX Inadequate Responders
patients with rheumatoid arthritis with an inadequate response to tumour necrosis
10. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association
1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum
include twenty-eight-joint counts. Development and validation in a prospective
Med 1983; 75:35–47.
modified scoring method on digitized and original radiographs. Arthritis Rheum
1998; 41:1583–90.
preliminary core set of disease activity measures for rheumatoid arthritis clinical trials.
The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis
15. van Gestel AM, Prevoo ML, van’t Hof MA, et al. Development and validation of
the European League Against Rheumatism response criteria for rheumatoid arthritis.
Comparison with the preliminary American College of Rheumatology and the World
Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum
differences in patients with rheumatoid arthritis: the patient’s perspective. J Rheumatol
17. Breedveld FC, Kalden JR. Appropriate and effective management of rheumatoid
and joint destruction after treatment with etanercept plus methotrexate: results from the
trial of etanercept and methotrexate with radiographic and patient outcomes.
rituximab is not dependent on clinical efficacy: results from a study in rheumatoid
arthritis patients with an inadequate response to one or more TNF inhibitors (REFLEX).
20. Thurlings RM, Nos K, Wijbrandts CA, et al. Synovial tissue response to rituximab:
mechanism of action and identification of biomarkers of response. Ann Rheum Dis
disease: a comprehensive review of mechanisms of action and identification of biomarkers.
Pharmaco Ther 2010; 125:464–75.
22. Vagnerová V, Bayer J, Howell K, et al. Depletion of B cells by a humanized anti-
patients (pts) have enhanced clinical response to rituximab (RTX) when compared
24. Tak PP, Cohen S, Emery P, et al. Baseline autoantibody status (RF, anti-CCP) and
clinical response following the first treatment course with rituximab. Arthritis Rheum
2006; 54(Suppl 9):833.
efficacy and safety of rituximab in patients with active rheumatoid arthritis despite
methotrexate treatment: results of a phase IIIB randomised, double-blind, placebo-
follow-up of the RA clinical trials and re-treatment population. Ann Rheum Dis
2009; 68(Suppl 3):76.
associated with low dose methotrexate treatment for rheumatoid arthritis. Scand J
with rheumatoid arthritis treated with infliximab: a retrospective review and case-
Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

P P Tak, W F Rigby, A Rubbert-Roth, et al.

*Ann Rheum Dis* 2011 70: 39-46 originally published online October 11, 2010
doi: 10.1136/ard.2010.137703

Updated information and services can be found at:
http://ard.bmj.com/content/70/1/39.full.html

These include:

**Data Supplement**
"Web Only Data"

**References**
This article cites 28 articles, 6 of which can be accessed free at:
http://ard.bmj.com/content/70/1/39.full.html#ref-list-1

Article cited in:
http://ard.bmj.com/content/70/1/39.full.html#related-urls

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Connective tissue disease (3156 articles)
- Degenerative joint disease (3410 articles)
- Immunology (including allergy) (3731 articles)
- Musculoskeletal syndromes (3660 articles)
- Rheumatoid arthritis (2388 articles)

**Notes**
To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/